Stocktoria
aTYR PHARMA INC ATYR
aTYR PHARMA INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 | $10.5M | $422,000 | — | — | — |
| R&D expense | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M | $17.3M | $14.0M | $20.4M | $30.1M | $42.8M |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M | -$15.9M | -$23.0M | -$32.8M | -$47.1M | -$57.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | -$49,000 |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M | -$16.2M | -$16.2M | -$34.5M | -$48.2M | -$57.9M |
| EPS (diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | — | — | — | — |
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M | -$15.3M | -$20.0M | -$31.1M | -$42.4M | -$52.9M |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M | -$15.5M | -$20.1M | -$31.7M | -$43.7M | -$53.5M |
| Cash & equivalents | $10.7M | $11.1M | $22.5M | $10.0M | $2.3M | $17.0M | $9.2M | $23.0M | $21.1M | $38.4M |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M | $38.7M | $36.2M | $52.7M | $89.4M | $80.5M |
| Shareholders' equity | $67.5M | $70.0M | $90.7M | $71.5M | $109.3M | $31.6M | $21.2M | $33.6M | $64.2M | $62.8M |
Growth · year-over-year · Revenue CAGR -12.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -19.1% | -33.4% | -96.6% | — | -100.0% | +2377.5% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.